Appendix

IPG Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Giovedì, Febbraio 8, 2024
Travel, Share repurchase, AI, Employment, Appendix, Depreciation, IPG, Software, Health, Pharmaceutical industry

Adjusted EBITA before restructuring charges was $628.5 million in the fourth quarter of 2023, compared to $568.4 million for the same period in 2022.

Key Points: 
  • Adjusted EBITA before restructuring charges was $628.5 million in the fourth quarter of 2023, compared to $568.4 million for the same period in 2022.
  • Revenue before billable expenses was $2.59 billion in the fourth quarter of 2023 compared to $2.55 billion in the fourth quarter of 2022.
  • Depreciation and amortization expense decreased by 9.4% during the fourth quarter of 2023, and decreased by 3.5% for the full year 2023.
  • During the fourth quarter of 2023, the Company declared and paid a common stock cash dividend of $0.310 per share, for a total of $117.9 million.

Transaction in Own Shares

Retrieved on: 
Giovedì, Febbraio 8, 2024
RNS, Council, Appendix, EUR, Treasury, European Parliament, London Stock Exchange, MAR

The repurchase of own shares is executed in public trading in accordance with Regulation No.

Key Points: 
  • The repurchase of own shares is executed in public trading in accordance with Regulation No.
  • 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052.
  • After the disclosed transactions, Nordea holds 11,264,110 treasury shares for capital optimisation purposes and 4,787,315 treasury shares for remuneration purposes.
  • Details of each transaction are included as an appendix to this announcement.

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

Retrieved on: 
Mercoledì, Febbraio 7, 2024
PRV, Steroid, Prostate cancer, COGS, Contingent value rights, TLX, Palliative care, Osteosarcoma, Patient, Safety, Nephrotoxicity, QSAM, FDA, Appendix, Sarcoma, Food, Term sheet, Brain, Disease, Pain management, Acquisition, Metastasis, Samarium, ODD, Radiopharmaceutical, Aplastic anemia, Glioma, ASX, Priority review, Medical imaging

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).

Key Points: 
  • MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).
  • QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.
  • Telix believes that 153Sm-DOTMP may benefit patients with metastatic lung and breast cancer, where many patients develop brain and bone metastases, and disease management often focusses on quality-of-life palliative care.
  • Telix will issue ordinary shares to the stockholders of QSAM at closing within its Listing Rule 7.1 placement capacity as consideration for the acquisition.

Mattel Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Mercoledì, Febbraio 7, 2024
Toys, Entertainment, Retail, Consumer, General Entertainment, Children, Licensing (Entertainment), Nature, EPS, Pandemic, Security (finance), COVID-19, Growth, GAAP, 600 (number), Failure, American Girl, Gross income, Tax, Transport, Regulation, Earnings per share, Food, Disclosure, Public expenditure, Eastern Standard, XV, Investment, Employment, Depreciation, Disease, Appendix, Risk, Accounting, Free cash flow, Sale, Webcast

At 5:00 p.m. (Eastern Standard Time) today, Mattel will host a conference call with investors and financial analysts to discuss its fourth quarter and full year financial results.

Key Points: 
  • At 5:00 p.m. (Eastern Standard Time) today, Mattel will host a conference call with investors and financial analysts to discuss its fourth quarter and full year financial results.
  • Mattel analyzes constant currency results to provide additional perspective on changes in underlying trends in Mattel’s operating performance.
  • The disclosure of the percentage change in constant currency enhances investor’s ability to compare financial results from one period to another.
  • Mattel presents changes in gross billings as a metric for comparing its aggregate, categorical, brand, and geographic results to highlight significant trends in Mattel’s business.

CRITEO REPORTS RECORD FOURTH QUARTER 2023 RESULTS

Retrieved on: 
Mercoledì, Febbraio 7, 2024
EPS, Traction, Media, Growth, Retail media, Marketing, Albertsons, GHG, Temperature, Carbon footprint, Adtech (company), Targets, Paris Agreement, Woman, Depreciation, Appendix, Commerce, Contribution, Science, Acquisition, Treasury, American depositary receipt, Share repurchase, Forecasting, Cryptocurrency

NEW YORK, Feb. 7, 2024 /PRNewswire/ -- Criteo S.A. (NASDAQ: CRTO) ("Criteo" or the "Company"), the commerce media company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • Revenue for Q4 2023 was $566 million, gross profit was $277 million and Contribution ex-TAC was $316 million.
  • Revenue for the fiscal year 2023 was $1.9 billion, gross profit was $863 million and Contribution ex-TAC was $1.0 billion.
  • Our record fourth quarter performance reflects building momentum for our  Commerce Media Platform and our strong focus on cost efficiencies, setting the stage for continued growth and robust profitability in 2024."
  • Contribution ex-TAC in the fourth quarter increased 12% year-over-year, or increased 10% at constant currency, to $316 million (Q4 2022: $283 million).

Transaction in Own Shares

Retrieved on: 
Mercoledì, Febbraio 7, 2024
RNS, Council, Appendix, EUR, Treasury, European Parliament, London Stock Exchange, MAR

The repurchase of own shares is executed in public trading in accordance with Regulation No.

Key Points: 
  • The repurchase of own shares is executed in public trading in accordance with Regulation No.
  • 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052.
  • After the disclosed transactions, Nordea holds 10,955,838 treasury shares for capital optimisation purposes and 4,787,315 treasury shares for remuneration purposes.
  • Details of each transaction are included as an appendix to this announcement.

Transaction in Own Shares

Retrieved on: 
Martedì, Febbraio 6, 2024
RNS, Council, Appendix, EUR, Treasury, European Parliament, London Stock Exchange, MAR

The repurchase of own shares is executed in public trading in accordance with Regulation No.

Key Points: 
  • The repurchase of own shares is executed in public trading in accordance with Regulation No.
  • 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052.
  • After the disclosed transactions, Nordea holds 10,543,532 treasury shares for capital optimisation purposes and 4,787,315 treasury shares for remuneration purposes.
  • Details of each transaction are included as an appendix to this announcement.

Nordea Bank Abp: Repurchase of own shares on 30.01.2024

Retrieved on: 
Lunedì, Febbraio 5, 2024
RNS, Council, Appendix, EUR, Treasury, European Parliament, London Stock Exchange, MAR

The repurchase of own shares is executed in public trading in accordance with Regulation No.

Key Points: 
  • The repurchase of own shares is executed in public trading in accordance with Regulation No.
  • 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052.
  • After the disclosed transactions, Nordea holds 6,104,766 treasury shares for capital optimisation purposes and 4,787,315 treasury shares for remuneration purposes.
  • On behalf of Nordea Bank Abp,
    This information is provided by RNS, the news service of the London Stock Exchange.

Transaction in Own Shares

Retrieved on: 
Lunedì, Febbraio 5, 2024
RNS, Council, Appendix, EUR, Treasury, European Parliament, London Stock Exchange, MAR

The repurchase of own shares is executed in public trading in accordance with Regulation No.

Key Points: 
  • The repurchase of own shares is executed in public trading in accordance with Regulation No.
  • 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052.
  • After the disclosed transactions, Nordea holds 8,158,764 treasury shares for capital optimisation purposes and 4,787,315 treasury shares for remuneration purposes.
  • Details of each transaction are included as an appendix to this announcement.

Transaction in Own Shares

Retrieved on: 
Lunedì, Febbraio 5, 2024
RNS, Council, Appendix, EUR, Treasury, European Parliament, London Stock Exchange, MAR

The repurchase of own shares is executed in public trading in accordance with Regulation No.

Key Points: 
  • The repurchase of own shares is executed in public trading in accordance with Regulation No.
  • 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052.
  • After the disclosed transactions, Nordea holds 7,460,236 treasury shares for capital optimisation purposes and 4,787,315 treasury shares for remuneration purposes.
  • Details of each transaction are included as an appendix to this announcement.